Oxford Biomedica PLC Logo

Oxford Biomedica PLC

A global CDMO specializing in cell and gene therapy and viral vector manufacturing.

OXB | IL

Overview

Corporate Details

ISIN(s):
GB00BDFBVT43
LEI:
213800S1GVQNXQ15K851
Country:
United Kingdom
Address:
WINDRUSH COURT, OX4 6LT OXFORD

Description

Oxford Biomedica (OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. A pioneer in the field, the company has extensive experience in viral vectors, the enabling technology for many advanced therapies. OXB provides end-to-end services to pharmaceutical and biotechnology partners, supporting programs from preclinical development through to commercial launch. Its core expertise includes the development and GMP manufacturing of various vector types, including lentivirus, adeno-associated virus (AAV), and adenovirus. The company offers proprietary technologies like its LentiVector™ platform, the first commercially approved lentiviral system, and its inAAVate™ platform for AAV, in addition to tech-transfer capabilities.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-08 16:30
PDMR Dealing
English 45.0 KB
2025-12-01 08:10
Total Voting Rights
English 11.0 KB
2025-11-03 18:05
Holding(s) in Company
English 25.0 KB
2025-11-03 08:25
Total Voting Rights
English 11.1 KB
2025-10-20 18:13
Director/PDMR Shareholding
English 19.5 KB
2025-10-16 08:00
Director/PDMR Shareholding
English 36.9 KB
2025-10-01 08:00
Total Voting Rights
English 11.6 KB
2025-09-23 08:00
Interim Results for 6 months ended 30 June 2025
English 732.3 KB
2025-08-22 16:36
PDMR Dealings
English 29.1 KB
2025-08-21 11:24
Holding(s) in Company
English 22.2 KB
2025-08-20 08:00
Admission of Shares and Total Voting Rights
English 10.9 KB
2025-08-15 14:45
PDMR Dealings
English 18.8 KB
2025-08-15 08:05
Results of Placing
English 43.5 KB
2025-08-14 18:02
Proposed Placing of New Ordinary Shares
English 168.6 KB
2025-08-01 08:00
OXB Secures New Loan Facility with Oaktree
English 16.3 KB

Automate Your Workflow. Get a real-time feed of all Oxford Biomedica PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Oxford Biomedica PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Oxford Biomedica PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.